| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
|
Chest
|
2008
|
7.94
|
|
2
|
Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
|
Chest
|
2012
|
4.82
|
|
3
|
Bleeding risk in very old patients on vitamin K antagonist treatment: results of a prospective collaborative study on elderly patients followed by Italian Centres for Anticoagulation.
|
Circulation
|
2011
|
2.60
|
|
4
|
A new warfarin dosing algorithm including VKORC1 3730 G > A polymorphism: comparison with results obtained by other published algorithms.
|
Eur J Clin Pharmacol
|
2012
|
2.07
|
|
5
|
Extended prophylaxis of venous thromboembolism with fondaparinux in patients undergoing major orthopaedic surgery in Italy: a cost-effectiveness analysis.
|
Intern Emerg Med
|
2009
|
2.03
|
|
6
|
Patient-level meta-analysis: effect of measurement timing, threshold, and patient age on ability of D-dimer testing to assess recurrence risk after unprovoked venous thromboembolism.
|
Ann Intern Med
|
2010
|
1.83
|
|
7
|
Risk of deep vein thrombosis: interaction between oral contraceptives and high factor VIII levels.
|
Haematologica
|
2004
|
1.73
|
|
8
|
Management of patients with patent foramen ovale and cryptogenic stroke: a collaborative, multidisciplinary, position paper: executive summary.
|
Catheter Cardiovasc Interv
|
2013
|
1.47
|
|
9
|
A multicentre randomised assessment of the DAWN AC computer-assisted oral anticoagulant dosage program.
|
Thromb Haemost
|
2009
|
1.46
|
|
10
|
Impact of glomerular filtration estimate on bleeding risk in very old patients treated with vitamin K antagonists. Results of EPICA study on the behalf of FCSA (Italian Federation of Anticoagulation Clinics).
|
Thromb Haemost
|
2012
|
1.45
|
|
11
|
Safety and feasibility of a diagnostic algorithm combining clinical probability, d-dimer testing, and ultrasonography for suspected upper extremity deep venous thrombosis: a prospective management study.
|
Ann Intern Med
|
2014
|
1.42
|
|
12
|
Repeated graft loss caused by recurrent hepatic artery thrombosis after liver transplantation.
|
Liver Transpl
|
2003
|
1.38
|
|
13
|
First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma.
|
Haematologica
|
2004
|
1.38
|
|
14
|
Bleeding risk assessment and management in atrial fibrillation patients. Executive Summary of a Position Document from the European Heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] Working Group on Thrombosis.
|
Thromb Haemost
|
2011
|
1.35
|
|
15
|
Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review.
|
Arch Intern Med
|
2010
|
1.27
|
|
16
|
Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis.
|
Europace
|
2011
|
1.22
|
|
17
|
Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy.
|
Blood
|
2002
|
1.15
|
|
18
|
Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, Part 1: Prevention.
|
Am J Hematol
|
2009
|
1.11
|
|
19
|
Coagulative disorders in human acute pancreatitis: role for the D-dimer.
|
Pancreas
|
2003
|
1.09
|
|
20
|
D-Dimer Testing in Patients With a First Unprovoked Venous Thromboembolism.
|
Ann Intern Med
|
2015
|
1.06
|
|
21
|
Usefulness of repeated D-dimer testing after stopping anticoagulation for a first episode of unprovoked venous thromboembolism: the PROLONG II prospective study.
|
Blood
|
2009
|
1.02
|
|
22
|
Clinical characteristics and management of cancer-associated acute venous thromboembolism: findings from the MASTER Registry.
|
Haematologica
|
2008
|
1.00
|
|
23
|
Using an age-dependent D-dimer cut-off value increases the number of older patients in whom deep vein thrombosis can be safely excluded.
|
Haematologica
|
2012
|
1.00
|
|
24
|
The factor VIII D1241E polymorphism is associated with decreased factor VIII activity and not with activated protein C resistance levels.
|
Thromb Haemost
|
2005
|
0.98
|
|
25
|
D-dimer levels in combination with residual venous obstruction and the risk of recurrence after anticoagulation withdrawal for a first idiopathic deep vein thrombosis.
|
Thromb Haemost
|
2005
|
0.94
|
|
26
|
The role of D-dimer and residual venous obstruction in recurrence of venous thromboembolism after anticoagulation withdrawal in cancer patients.
|
Haematologica
|
2005
|
0.92
|
|
27
|
Management of patients with patent foramen ovale and cryptogenic stroke: a collaborative, multidisciplinary, position paper.
|
Catheter Cardiovasc Interv
|
2013
|
0.91
|
|
28
|
Factors associated with the timing of diagnosis of venous thromboembolism: results from the MASTER registry.
|
Thromb Res
|
2007
|
0.89
|
|
29
|
Multicenter evaluation of a new quantitative highly sensitive D-dimer assay, the Hemosil D-dimer HS 500, in patients with clinically suspected venous thromboembolism.
|
Thromb Res
|
2009
|
0.89
|
|
30
|
Evidence and clinical judgment: vena cava filters.
|
Thromb Haemost
|
2014
|
0.88
|
|
31
|
Transcatheter patent foramen ovale closure mitigates aura migraine headaches abolishing spontaneous right-to-left shunting.
|
Am Heart J
|
2006
|
0.88
|
|
32
|
The MASTER registry on venous thromboembolism: description of the study cohort.
|
Thromb Res
|
2007
|
0.88
|
|
33
|
Spontaneous large right-to-left shunt and migraine headache with aura are risk factors for recurrent stroke in patients with a patent foramen ovale.
|
Int J Cardiol
|
2006
|
0.86
|
|
34
|
Comparison of results of percutaneous closure of patent foramen ovale for paradoxical embolism in patients with versus without thrombophilia.
|
Am J Cardiol
|
2004
|
0.85
|
|
35
|
Plasma MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 during human orthotopic liver transplantation. The effect of aprotinin and the relation to ischemia/reperfusion injury.
|
Thromb Haemost
|
2004
|
0.85
|
|
36
|
Foetal cerebral hemispheric atrophy and porencephaly after intrauterine exposure to maternal warfarin for mechanical prosthetic heart valve.
|
Prenat Diagn
|
2008
|
0.85
|
|
37
|
Analysis of agreement between Duplex ultrasound scanning and arteriography in patients with lower limb artery disease.
|
J Cardiovasc Med (Hagerstown)
|
2007
|
0.84
|
|
38
|
Gender differences of bleeding and stroke risk in very old atrial fibrillation patients on VKA treatment: results of the EPICA study on the behalf of FCSA (Italian Federation of Anticoagulation Clinics).
|
Thromb Res
|
2012
|
0.84
|
|
39
|
D-dimer and factor VIII are independent risk factors for recurrence after anticoagulation withdrawal for a first idiopathic deep vein thrombosis.
|
Thromb Res
|
2008
|
0.84
|
|
40
|
Consumption of clotting factors in severe haemophilia patients undergoing prophylaxis and on-demand treatment in Italy.
|
Transfus Med
|
2011
|
0.84
|
|
41
|
Abnormally short activated partial thromboplastin time values are associated with increased risk of recurrence of venous thromboembolism after oral anticoagulation withdrawal.
|
Br J Haematol
|
2006
|
0.84
|
|
42
|
Pharmacodynamics of low molecular weight heparin in patients undergoing bariatric surgery: a prospective, randomised study comparing two doses of parnaparin (BAFLUX study).
|
Thromb Res
|
2009
|
0.83
|
|
43
|
Residual emboli on lung perfusion scan or multidetector computed tomography after a first episode of acute pulmonary embolism.
|
Intern Emerg Med
|
2011
|
0.83
|
|
44
|
Different cut-off values of quantitative D-dimer methods to predict the risk of venous thromboembolism recurrence: a post-hoc analysis of the PROLONG study.
|
Haematologica
|
2008
|
0.83
|
|
45
|
Use of D-dimer testing to determine duration of anticoagulation, risk of cardiovascular events and occult cancer after a first episode of idiopathic venous thromboembolism: the extended follow-up of the PROLONG study.
|
J Thromb Thrombolysis
|
2009
|
0.83
|
|
46
|
Evaluation of a new automated panel of assays for the detection of anti-PF4/heparin antibodies in patients suspected of having heparin-induced thrombocytopenia.
|
Thromb Haemost
|
2010
|
0.82
|
|
47
|
Assessing recurrence risk following acute venous thromboembolism: use of algorithms.
|
Curr Opin Pulm Med
|
2013
|
0.82
|
|
48
|
Evidence and clinical judgment: Treatment of cerebral vein thrombosis.
|
Thromb Haemost
|
2010
|
0.81
|
|
49
|
Role of family history in identifying women with thrombophilia and higher risk of venous thromboembolism during oral contraception.
|
Arch Intern Med
|
2003
|
0.81
|
|
50
|
Update on the predictive value of D-dimer in patients with idiopathic venous thromboembolism.
|
Thromb Res
|
2010
|
0.81
|
|
51
|
Comorbidities, alone and in combination with D-dimer, as risk factors for recurrence after a first episode of unprovoked venous thromboembolism in the extended follow-up of the PROLONG study.
|
Thromb Haemost
|
2010
|
0.81
|
|
52
|
Old and new heparins.
|
Thromb Res
|
2011
|
0.81
|
|
53
|
Long-term efficacy of transcatheter patent foramen ovale closure on migraine headache with aura and recurrent stroke.
|
Catheter Cardiovasc Interv
|
2006
|
0.81
|
|
54
|
A multicenter evaluation of a new quantitative highly sensitive D-dimer assay for exclusion of venous thromboembolism.
|
Thromb Haemost
|
2008
|
0.80
|
|
55
|
Patient-level compared with study-level meta-analyses demonstrate consistency of D-dimer as predictor of venous thromboembolic recurrences.
|
J Clin Epidemiol
|
2013
|
0.80
|
|
56
|
[Multidisciplinary position paper on the management of patent foramen ovale in the presence of cryptogenic cerebral ischemia - Italian version 2013].
|
G Ital Cardiol (Rome)
|
2013
|
0.80
|
|
57
|
Long-term death and recurrence in patients with acute venous thromboembolism: the MASTER registry.
|
Thromb Res
|
2012
|
0.80
|
|
58
|
Fibrin D-dimer testing for venous and arterial thrombotic disease.
|
Semin Vasc Med
|
2005
|
0.80
|
|
59
|
A multicentre randomised clinical endpoint study of PARMA 5 computer-assisted oral anticoagulant dosage.
|
Br J Haematol
|
2008
|
0.79
|
|
60
|
Recurrence rate after a first venous thrombosis in patients with familial thrombophilia.
|
Arterioscler Thromb Vasc Biol
|
2005
|
0.79
|
|
61
|
Thalidomide-dexamethasone as up-front therapy for patients with newly diagnosed multiple myeloma: thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low-dose warfarin.
|
Eur J Haematol
|
2010
|
0.79
|
|
62
|
Evaluation of the prevalence of severe hyperhomocysteinemia in adult patients with thrombosis who underwent screening for thrombophilia.
|
Thromb Res
|
2013
|
0.79
|
|
63
|
Biological variation of INR in stable patients on long-term anticoagulation with warfarin.
|
Thromb Res
|
2012
|
0.78
|
|
64
|
Validation of STA-Liatest D-Di assay for exclusion of pulmonary embolism according to the latest Clinical and Laboratory Standard Institute/Food and Drug Administration guideline. Results of a multicenter management study.
|
Blood Coagul Fibrinolysis
|
2016
|
0.78
|
|
65
|
Modulation of factor V levels in plasma by polymorphisms in the C2 domain.
|
Arterioscler Thromb Vasc Biol
|
2003
|
0.78
|
|
66
|
Risk factors for venous thromboembolism in the elderly: results of the master registry.
|
Blood Coagul Fibrinolysis
|
2008
|
0.78
|
|
67
|
Prevention of venous thromboembolism in immobilized neurological patients: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET).
|
Thromb Res
|
2009
|
0.78
|
|
68
|
Low-intensity oral anticoagulant plus low-dose aspirin during the first six months versus standard-intensity oral anticoagulant therapy after mechanical heart valve replacement: a pilot study of low-intensity warfarin and aspirin in cardiac prostheses (LIWACAP).
|
Clin Appl Thromb Hemost
|
2007
|
0.78
|
|
69
|
Abnormal Protac-induced coagulation inhibition chromogenic assay results are associated with an increased risk of recurrent venous thromboembolism.
|
J Thromb Thrombolysis
|
2010
|
0.77
|
|
70
|
A new rapid bedside assay for quantitative testing of D-Dimer (Cardiac D-Dimer) in the diagnostic work-up for deep vein thrombosis.
|
Thromb Res
|
2003
|
0.77
|
|
71
|
Subsegmental pulmonary embolism: is the emperor still naked?
|
Radiol Med
|
2013
|
0.77
|
|
72
|
Influence of age, sex and vitamin status on fasting and post-methionine load plasma homocysteine levels.
|
Haematologica
|
2002
|
0.77
|
|
73
|
Effects of unfractioned heparin and low-molecular-weight heparin on osteoprotegerin and RANKL plasma levels in haemodialysis patients.
|
Nephrol Dial Transplant
|
2010
|
0.77
|
|
74
|
Diagnosis and treatment of pulmonary embolism: a multidisciplinary approach.
|
Multidiscip Respir Med
|
2013
|
0.77
|
|
75
|
D-dimer, oral anticoagulation, and venous thromboembolism recurrence.
|
Semin Vasc Med
|
2005
|
0.77
|
|
76
|
Prevention of VTE in multiple myeloma patients.
|
Thromb Res
|
2007
|
0.77
|
|
77
|
Psychological impact of testing for thrombophilic alterations.
|
Thromb Haemost
|
2006
|
0.76
|
|
78
|
The negative predictive value of D-dimer on the risk of recurrent venous thromboembolism in patients with multiple previous events: a prospective cohort study (the PROLONG PLUS study).
|
Am J Hematol
|
2012
|
0.76
|
|
79
|
Recurrence of ICH after resumption of anticoagulation with VK antagonists: CHIRONE study.
|
Neurology
|
2014
|
0.76
|
|
80
|
Prevalence of risk factors for venous thromboembolism in the Italian population: results of a cross-sectional study from the Master Registry.
|
Intern Emerg Med
|
2011
|
0.76
|
|
81
|
Extended treatment for venous thromboembolism: how long is long enough?
|
Curr Hematol Rep
|
2004
|
0.76
|
|
82
|
Age and gender specific cut-off values to improve the performance of D-dimer assays to predict the risk of venous thromboembolism recurrence.
|
Intern Emerg Med
|
2011
|
0.76
|
|
83
|
Oral anticoagulant therapy in venous thromboembolism.
|
Semin Vasc Med
|
2003
|
0.76
|
|
84
|
Low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism.
|
N Engl J Med
|
2003
|
0.75
|
|
85
|
Warfarin anticoagulation in children made easier.
|
Thromb Res
|
2005
|
0.75
|
|
86
|
The influence of VKORC1 3730 G > A polymorphism on warfarin dose: reply.
|
Eur J Clin Pharmacol
|
2012
|
0.75
|
|
87
|
External quality assessment (EQA) for CoaguChek monitors.
|
Thromb Haemost
|
2010
|
0.75
|
|
88
|
G1691A factor V and G20210A FII mutations, acute ischemic stroke of unknown cause, and patent foramen ovale.
|
Thromb Res
|
2012
|
0.75
|
|
89
|
[The BAFTA study].
|
G Ital Cardiol (Rome)
|
2008
|
0.75
|
|
90
|
Risk of early recurrent fetal loss and levels of thrombin-activatable fibrinolysis inhibitor.
|
Thromb Res
|
2011
|
0.75
|
|
91
|
Stroke/thromboembolism and intracranial hemorrhage in a real-world atrial fibrillation population: the Complications of Atrial Fibrillation in the Bologna Area (CAFBO) study.
|
Chest
|
2014
|
0.75
|
|
92
|
Reduced inhibition of activated prothrombin by heparin and venous thromboembolism: heparin resistance revisited.
|
Haematologica
|
2002
|
0.75
|
|
93
|
A commentary: to screen for calf DVT or not to screen? The highly variable practice among Italian centers highlights this important and still unresolved clinical option. Results from the Italian MASTER registry.
|
Thromb Haemost
|
2008
|
0.75
|
|
94
|
Inherited and acquired thrombophilic alterations in patients with superficial vein thrombosis of lower limbs.
|
Thromb Haemost
|
2014
|
0.75
|
|
95
|
Thrombophilic risk factors and peripheral arterial disease severity.
|
Thromb Haemost
|
2010
|
0.75
|
|
96
|
A FV multiallelic marker detects genetic components of APC resistance contributing to venous thromboembolism in FV Leiden carriers.
|
Thromb Haemost
|
2003
|
0.75
|
|
97
|
Comparative evaluation of D-dimer assays for exclusion of deep venous thrombosis in symptomatic outpatients.
|
Thromb Res
|
2003
|
0.75
|
|
98
|
D-dimer testing and recurrent venous thromboembolism after unprovoked pulmonary embolism: A post-hoc analysis of the prolong extension study.
|
Thromb Haemost
|
2008
|
0.75
|
|
99
|
Obstetric complications and pregnancy-related venous thromboembolism: the effect of low-molecular-weight heparin on their prevention in carriers of factor V Leiden or prothrombin G20210A mutation.
|
Thromb Haemost
|
2012
|
0.75
|
|
100
|
The influence of factor V Leiden and G20210A prothrombin mutation on the presence of residual vein obstruction after idiopathic deep-vein thrombosis of the lower limbs.
|
Thromb Haemost
|
2013
|
0.75
|
|
101
|
Biological Determinants of Fasting and Postload Plasma Homocysteine Levels in Healthy Italian Subjects.
|
Turk J Haematol
|
2002
|
0.75
|
|
102
|
Intracranial hemorrhage recurrence on vitamin K antagonist: severity of the first episode and HASBLED score fail to identify high-risk patients from the CHIRONE study.
|
Blood Coagul Fibrinolysis
|
2017
|
0.75
|
|
103
|
Asymptomatic carriership of factor V Leiden and genotypes of the fibrinogen gene cluster.
|
Br J Haematol
|
2003
|
0.75
|
|
104
|
Special indications for vitamin K antagonists: a review.
|
Intern Emerg Med
|
2011
|
0.75
|
|
105
|
Oral contraceptive use in women with poor anticoagulant response to activated protein C but not carrying the factor V Leiden mutation increases the risk of venous thrombosis.
|
Thromb Haemost
|
2004
|
0.75
|
|
106
|
Thromboprophylaxis following cesarean delivery: one site prospective pilot study to evaluate the application of a risk score model.
|
Thromb Res
|
2011
|
0.75
|